What is NRXP's current stock price?

NRXP (NRx Pharmaceuticals, Inc.) is currently trading at $3.22 with a market cap of $55.7M.

What sector is NRx Pharmaceuticals, Inc. in?

NRx Pharmaceuticals, Inc. (NRXP) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is NRXP a good stock to buy?

Analysts have a Buy consensus on NRXP with a price target of $2.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NRXP NRx Pharmaceuticals, Inc.

Healthcare

$3.22+5.23%ClosedMarket Cap: $55.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-7.53

P/S

24.27

EV/EBITDA

-1.62

DCF Value

$0.74

FCF Yield

-26.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

37.1%

Operating Margin

-749.7%

Net Margin

-1070.3%

ROE

107.7%

ROA

-206.2%

ROIC

133.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$1.1M	$-1.4M	$—
Q4 null	$983.0K	$360.0K	$—
FY null	$1.2M	$-28.6M	$—
Q3 null	$242.0K	$-5.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.00

Target (Median)

$2.00

Target Range

$2.00 - $2.00

0 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

D. Boral CapitalBuy

2026-05-05

HC Wainwright & Co.Buy

2026-04-27

Ascendiant CapitalBuy

2026-04-27

BTIGBuy

2026-03-24

D. Boral CapitalBuy

2026-03-24

Trading Activity

Insider Trades

View All

Casper Joseph Michaelofficer: Chief Operating Officer

SellTue Feb 17

Casper Joseph Michaelofficer: Chief Operating Officer

SellTue Feb 17

McBride Dennisdirector

SellWed Sep 10

Javitt Jonathan Cdirector, 10 percent owner, officer: Chairman and Chief Scientist

SellWed Sep 10

Hurvitz Chaimdirector

SellWed Sep 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.02

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Peers

COEP

CUE